Conference: AAIC 2026 | Dates: July 12-15, 2026 | Location: Excel London, UK
Metabolic dysfunction is increasingly recognized as a central feature of Alzheimer's disease, with brain insulin resistance, mitochondrial dysfunction, and impaired glucose metabolism contributing to cognitive decline. AAIC 2026 features comprehensive coverage of metabolic interventions, from novel therapeutics to lifestyle modifications.
- Reduced cerebral glucose uptake: Early feature of AD
- PET FDG imaging markers: Diagnostic and prognostic value
- Relationship to amyloid and tau: Independent pathological contributions
- Complex I impairment: Electron transport chain defects
- ATP production deficits: Energy crisis in neurons
- Reactive oxygen species: Oxidative stress from mitochondria
- IRS-1 signaling defects: Downstream pathway disruption
- PI3K/Akt impairment: Synaptic plasticity effects
- FOXO transcription factors: Gene expression alterations
- Intranasal insulin: Direct CNS delivery approaches
- Insulin sensitizers: PPARγ agonists and related compounds
- GLP-1 receptor agonists: Incretin effects in brain
¶ Ketone Body Utilization
- BHB (β-hydroxybutyrate): Alternative brain fuel
- Ketogenic diets: Dietary interventions
- Exogenous ketones: Supplementation strategies
- Glucose-to-ketone switch: Enhancing brain resilience
- MCT transporters: Monocarboxylate transporters in brain
- Age-related decline: How metabolic flexibility changes
- Cholesterol synthesis: Local production in neurons
- APOE and lipid transport: Role of APOE4
- Membrane lipid composition: Effects on synaptic function
- Statins: Cholesterol-lowering in AD trials
- Liver X receptor agonists: Nuclear receptor targeting
- Fatty acid oxidation modulators: Metabolic pathway effects
- Metformin: AMPK activation and beyond
- GLP-1 analogues: Liraglutide, semaglutide in trials
- SGLT2 inhibitors: Renal glucose reabsorption inhibition
- Mitochondrial antioxidants: MitoQ, CoQ10
- Complex I optimizers: Electron transfer enhancers
- Mitophagy inducers: Enhancing mitochondrial quality control
¶ Dietary and Lifestyle Interventions
- Classic ketogenic diet: High-fat, low-carbohydrate
- MCT oil supplementation: Medium-chain triglycerides
- Time-restricted eating: Fasting effects on brain
- Intermittent fasting: 16:8 and similar patterns
- Caloric restriction mimetics: Pharmacologic approaches
- Autophagy induction: Cellular cleanup mechanisms
- NMN (nicotinamide mononucleotide): NAD+ precursor
- NR (nicotinamide riboside): Alternative precursor
- PARP inhibitors: Preserving NAD+ pools
- AICAR: AMPK agonist in development
- Metformin: Established AMPK activator
- Herbal compounds: Natural AMPK activators
- "Brain Insulin Resistance: From Mechanism to Therapy"
- "Ketone Bodies as Therapeutic Agents in Alzheimer's"
- "Mitochondrial Dysfunction: The Missing Link in AD"
- "Metabolic Biomarkers in Clinical Trials"
- "FDG-PET: Beyond Diagnosis"
- "Dietary Interventions for Cognitive Health"
- AAIC 2026 Conference
- AAIC 2026: Therapeutic Approaches
- AAIC 2026: Neuroinflammation
- Alzheimer's Disease